Last reviewed · How we verify
Saline 0.9% (matching placebo)
Saline 0.9% is an isotonic sodium chloride solution that serves as a physiologically inert vehicle for drug delivery or fluid replacement.
Saline 0.9% is an isotonic sodium chloride solution that serves as a physiologically inert vehicle for drug delivery or fluid replacement. Used for Placebo control in clinical trials.
At a glance
| Generic name | Saline 0.9% (matching placebo) |
|---|---|
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Normal saline (0.9% NaCl) matches the osmolarity of human blood plasma (~308 mOsm/L) and is used as a standard placebo control in clinical trials because it has no pharmacological activity. It maintains fluid balance and electrolyte homeostasis without therapeutic effect, making it an ideal inert comparator for blinded studies.
Approved indications
- Placebo control in clinical trials
Common side effects
- No expected adverse events (inert placebo)
Key clinical trials
- A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) (PHASE3)
- Tocilizumab in Lung Transplantation (PHASE2)
- Study of ARO-CFB in Adult Healthy Volunteers (PHASE1)
- Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age (PHASE1, PHASE2)
- Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis (PHASE1)
- The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies (PHASE3)
- Repurposing Semaglutide for the Treatment of Cocaine Use Disorder (PHASE2)
- Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: